Anxiety and Related Sleep Disorders - NAFTA

Revenue in the Anxiety and Related Sleep Disorders market is projected to reach US$3.60bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.76%, resulting in a market volume of US$3.74bn by 2029.
In global comparison, most revenue will be generated United States (US$3.21bn in 2024).
In relation to total population figures, per person revenues of US$110.70 are generated in 2024.

The Anxiety and Related Sleep Disorders market covers sales of three drug classes: anxiolytics, hypnotics, and sedatives. These classes contain different types of drugs, such as benzodiazepines, anticonvulsants, and antihistamines, that reduce anxiety and insomnia symptoms caused by anxiety. These medications mainly fall into the category of prescription drugs.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Pfizer, Bristol-Myers Squibb, GlaxoSmithKline PLC, Johnson & Johnson, and Merck & Co.

Pharmaceutical sales and consumption of anxiolytics
Pharmaceutical sales and consumption hypnotics and sedatives

Non-mental health related sleep disorders
Any other anxiety medications
Psychotherapy

The Anxiety and Related Sleep Disorders market in NAFTA is experiencing significant growth due to changing customer preferences, emerging trends, and local special circumstances.

Customer preferences: Customers in the NAFTA region are increasingly seeking solutions for anxiety and related sleep disorders. This can be attributed to several factors, including the growing awareness and understanding of mental health issues, increased stress levels in the modern lifestyle, and the availability of a wide range of treatment options. As a result, there is a rising demand for pharmaceutical products, therapy services, and alternative treatments such as natural remedies and meditation techniques.

Trends in the market: One of the major trends in the Anxiety and Related Sleep Disorders market in NAFTA is the shift towards personalized and holistic approaches to treatment. Customers are looking for tailored solutions that address their specific needs and preferences. This has led to the development of innovative products and services, such as personalized medication regimens, virtual therapy sessions, and wearable devices that track sleep patterns and provide real-time feedback.Another trend in the market is the increasing use of technology to improve diagnosis and treatment. Telemedicine and digital health platforms are gaining popularity, allowing patients to access healthcare services remotely and receive personalized treatment plans. Additionally, the use of artificial intelligence and machine learning algorithms is helping healthcare professionals to better understand and predict anxiety and sleep disorders, leading to more effective interventions.

Local special circumstances: The Anxiety and Related Sleep Disorders market in NAFTA is also influenced by local special circumstances. For example, the United States has a high prevalence of anxiety disorders, with a significant portion of the population seeking treatment. This has created a large market for pharmaceutical companies, therapy providers, and other healthcare services. In Canada, there is a growing focus on mental health awareness and support, leading to increased investments in research and development, as well as the expansion of mental health services. Mexico, on the other hand, is experiencing a rise in urbanization and lifestyle changes, which can contribute to higher stress levels and an increased demand for anxiety and sleep disorder treatments.

Underlying macroeconomic factors: Several macroeconomic factors are driving the growth of the Anxiety and Related Sleep Disorders market in NAFTA. These include the overall economic growth in the region, which has led to increased healthcare spending and improved access to healthcare services. Additionally, the aging population in NAFTA countries is more prone to anxiety and sleep disorders, creating a larger customer base for the market. Finally, the increasing acceptance and destigmatization of mental health issues in society have encouraged individuals to seek help and treatment, further driving the demand for anxiety and sleep disorder solutions.Overall, the Anxiety and Related Sleep Disorders market in NAFTA is witnessing significant growth due to changing customer preferences, emerging trends, local special circumstances, and underlying macroeconomic factors. This presents opportunities for companies operating in the market to develop innovative products and services that cater to the specific needs of customers in the region.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.